PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

BriaCell Therapeutics shares are trading lower by 40% Thursday afternoon. The company announced the pricing of a $5.5 million public offering.

Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.

BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, Thursday announced the pricing of an underwritten public ...

BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...

Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

Equities researchers at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a ...

Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a report ...

Short interest in BriaCell Therapeutics Corp (NASDAQ:BCTX) decreased during the last reporting period, falling from 745.07K to 534.83K. This put 1.66% of the company's publicly available shares short.